Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01154816CT.gov Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Germ Cell Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Etoposide (this asset) | Children's Oncology Group | P3 | BB · 66 |
| Carboplatin | Children's Oncology Group | P3 | BB |
| Nivestim | Children's Oncology Group | P2 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Children's Oncology Group | P3 | B |
| Bleomycin | Children's Oncology Group | P3 | B |
| Alisertib | Children's Oncology Group | P2 | B |
| Tazemetostat | National Cancer Institute (NCI) | P2 | B |
| Palbociclib | National Cancer Institute (NCI) | P2 | B |
+27 more in the Malignant Germ Cell Tumor cohort
Other indications for Etoposide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Megakaryoblastic Leukemia | — | P3 | BBB · 79 |
| Acute Monocytic Leukemia | — | P3 | BBB · 79 |
| Acute Myeloblastic Leukemia With Maturation | — | P3 | BBB · 79 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Etoposide in Malignant Germ Cell Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/etoposide-malignant-germ-cell-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →